Skip to main content
. Author manuscript; available in PMC: 2014 Sep 11.
Published in final edited form as: Hypertens Res. 2011 Sep 22;34(12):1257–1262. doi: 10.1038/hr.2011.110

Figure 2.

Figure 2

Effects on improved baroreflex sensitivity (BRS) elicited by bradykinin potentiating nonapeptide (BPP)9a of the Ang-(1–7) receptor antagonist, d-Ala or the bradykinin (BK)–B2 receptor antagonist, HOE-140, in male (mRen2)27 rats. BRS changes (a, d), MAP changes (b, e) and HR changes (c, f) before and after microinjection of d-Ala7-Ang-(1–7) (d-Ala; a–c) or HOE-140 (d–f). The BRS improvement elicited by BPP9α was reversed completely by nTS microinjection of d-Ala. Microinjection of the BK–B2 receptor blocker HOE-140 into the nTS did not significantly alter the improvement in BRS elicited by BPP9α. Neither d-Ala nor HOE-140 significantly altered MAP and HR. *P<0.05 vs. baseline, #P<0.05 vs. 60 and 90–120 min.